Semiannual Report — FY2026 H1
What ROHTO PHARMACEUTICAL CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-13View the original on EDINET
How much it says
47Typical
What moved here
6named for the first time
Its own wording
26terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, マジック・コッド社 and 1 other company were newly included in the scope of consolidation following the acquisition of their shares. Net sales increased and operating profit rose, while ordinary profit and interim net income attributable to owners of the parent declined.
Komori's summary of this document, not the document's own words.47Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
37
Thin
67
Detailed
62
Detailed
0
Almost nothing
12
Almost nothing
77
Very detailed
62
Detailed
53
Typical
55
Typical
10
Almost nothing
R&D spend71億円Money spent making new things.
Cash left over97億円Cash from the business, less what went into equipment.
Spent on equipment66億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.